SHANGHAI, June 30 (Reuters) - Innovent Biologics ( IVBXF )
has entered into an agreement that grants it sole
commercialization rights for Eli Lilly's ( LLY ) breast cancer
drug Verzenios in mainland China, the Chinese drugmaker said
Tuesday.
Lilly will continue manufacturing, supplying and developing
the drug, it said in a statement.